Page last updated: 2024-10-28

beta-thujaplicin and Carcinoma, Hepatocellular

beta-thujaplicin has been researched along with Carcinoma, Hepatocellular in 1 studies

beta-thujaplicin: structure
beta-thujaplicin : A monoterpenoid that is cyclohepta-2,4,6-trien-1-one substituted by a hydroxy group at position 2 and an isopropyl group at position 4. Isolated from Thuja plicata and Chamaecyparis obtusa, it exhibits antimicrobial activities.

Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhang, G1
He, J1
Ye, X1
Zhu, J1
Hu, X1
Shen, M1
Ma, Y1
Mao, Z1
Song, H1
Chen, F1

Other Studies

1 other study available for beta-thujaplicin and Carcinoma, Hepatocellular

ArticleYear
β-Thujaplicin induces autophagic cell death, apoptosis, and cell cycle arrest through ROS-mediated Akt and p38/ERK MAPK signaling in human hepatocellular carcinoma.
    Cell death & disease, 2019, 03-15, Volume: 10, Issue:4

    Topics: Aged; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagic Cell Death; Autophagosomes;

2019